Latest news with #GCBiopharma
Yahoo
20-07-2025
- Business
- Yahoo
3 Asian Stocks Estimated To Be Trading Up To 39.1% Below Intrinsic Value
As Asian markets navigate a landscape marked by political uncertainties and trade tensions, investors are increasingly looking for opportunities that promise value amidst volatility. Identifying stocks trading below their intrinsic value can be a prudent strategy in such an environment, offering potential upside as market conditions stabilize. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) PropNex (SGX:OYY) SGD1.34 SGD2.67 49.7% Medy-Tox (KOSDAQ:A086900) ₩163000.00 ₩322233.66 49.4% Mandom (TSE:4917) ¥1427.00 ¥2828.12 49.5% Lucky Harvest (SZSE:002965) CN¥35.75 CN¥70.35 49.2% Japan Eyewear Holdings (TSE:5889) ¥2151.00 ¥4222.53 49.1% HL Holdings (KOSE:A060980) ₩41300.00 ₩81736.71 49.5% Cosmax (KOSE:A192820) ₩243000.00 ₩483155.97 49.7% Astroscale Holdings (TSE:186A) ¥673.00 ¥1324.01 49.2% ALUX (KOSDAQ:A475580) ₩11490.00 ₩22617.71 49.2% Accton Technology (TWSE:2345) NT$798.00 NT$1590.11 49.8% Click here to see the full list of 255 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. GC Biopharma Overview: GC Biopharma Corp. is a biopharmaceutical company that develops and sells pharmaceutical drugs both in South Korea and internationally, with a market cap of approximately ₩1.75 trillion. Operations: The company's revenue primarily comes from the manufacturing and sales of pharmaceuticals, totaling ₩1.65 trillion, complemented by ₩200.20 million from diagnosis and analysis of samples, etc. Estimated Discount To Fair Value: 38.4% GC Biopharma is trading at 38.4% below its estimated fair value, highlighting its potential as an undervalued stock based on cash flows. Despite a low forecasted return on equity of 4.3%, the company has become profitable this year with significant earnings growth expected to outpace the KR market. Recent product approvals and trials, such as BARYCELA's entry into Vietnam and Hunterase's promising Phase 3 results, bolster revenue prospects amidst robust sector demand. Upon reviewing our latest growth report, GC Biopharma's projected financial performance appears quite optimistic. Navigate through the intricacies of GC Biopharma with our comprehensive financial health report here. Beijing Kawin Technology Share-Holding Overview: Beijing Kawin Technology Share-Holding Co., Ltd. is a biopharmaceutical company that offers treatment solutions for viral and immune diseases in China, with a market cap of CN¥5.38 billion. Operations: The company's revenue primarily comes from its Medicine Manufacturing segment, which generated CN¥1.25 billion. Estimated Discount To Fair Value: 39.1% Beijing Kawin Technology Share-Holding is trading 39.1% below its estimated fair value of CN¥52.74, presenting it as an undervalued stock based on cash flows. Despite a forecasted earnings growth of 20.67% per year, which is slower than the market average, revenue growth at 20% annually outpaces the market's 12.5%. Recent Q1 results show increased sales and net income compared to last year, although dividends remain minimally covered by free cash flows. The analysis detailed in our Beijing Kawin Technology Share-Holding growth report hints at robust future financial performance. Click to explore a detailed breakdown of our findings in Beijing Kawin Technology Share-Holding's balance sheet health report. Rayhoo Motor DiesLtd Overview: Rayhoo Motor Dies Co., Ltd. designs, develops, manufactures, and sells stamping dies and auto welding lines both in China and internationally, with a market cap of CN¥8.59 billion. Operations: Rayhoo Motor Dies Ltd generates its revenue from the design, development, manufacturing, and sale of stamping dies and auto welding lines across domestic and international markets. Estimated Discount To Fair Value: 32.3% Rayhoo Motor Dies Ltd. trades at 32.3% below its estimated fair value of CNY 60.66, highlighting its undervaluation based on cash flows. Despite earnings growth forecasts of 21.8% annually, slightly below the market average, revenue is expected to grow robustly at 25.8%, surpassing the market's rate. Recent Q1 results show significant sales and net income increases year-on-year, though dividends are not well covered by free cash flows. Our comprehensive growth report raises the possibility that Rayhoo Motor DiesLtd is poised for substantial financial growth. Unlock comprehensive insights into our analysis of Rayhoo Motor DiesLtd stock in this financial health report. Where To Now? Embark on your investment journey to our 255 Undervalued Asian Stocks Based On Cash Flows selection here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe. Ready To Venture Into Other Investment Styles? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A006280 SHSE:688687 and SZSE:002997. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Korea Herald
17-07-2025
- Business
- Korea Herald
GC Biopharma Receives Marketing Authorization for BARYCELA in Vietnam
YONGIN, South Korea, July 17, 2025 /PRNewswire/ -- GC Biopharma ( a South Korean pharmaceutical company, announced that its varicella vaccine BARYCELA has received marketing authorization from the Drug Administration of Vietnam (DAV). Following domestic approval in 2020 and WHO Pre-Qualification (PQ) in 2023, GC Biopharma has been accelerating individual country registrations as part of its dual-track strategy—pursuing both global procurement channels and direct market entry initiatives. To obtain approval in Vietnam, GC Biopharma conducted local clinical trials to establish the product's safety and immunogenicity. This achievement highlights the company's ability to meet the increasingly stringent regulatory standards set by DAV. As a vaccine administered primarily to children, quality certification holds particular importance in the varicella segment. GC Biopharma plans to establish stable annual revenue in Vietnam by leveraging its local affiliate to engage directly in sales activities, in consideration of the country's private market-oriented vaccine distribution system. From 2018 to 2021, Vietnam's private vaccine market recorded a compound annual growth rate (CAGR) of 32%, reaching approximately USD 300 million in 2021. Varicella vaccines accounted for nearly 10% of the private market [1], with demand for private vaccinations continuing to grow steadily. "This marketing authorization represents more than a product export—it is the result of a localization strategy and a significant step toward expansion in Southeast Asia," said Jae Woo Lee, Head of Development Department at GC Biopharma. "We will continue to strengthen our position as a trusted vaccine brand by delivering clinical and quality standards that meet global expectations." BARYCELA is a live attenuated varicella vaccine developed by GC Biopharma using its proprietary MAV/06 virus strain. The vaccine is characterized by high viral titer and manufacturing yield. Notably, BARYCELA is the world's first varicella vaccine produced without antibiotics, utilizing a fully aseptic manufacturing process. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo ® (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Sohee Kim Yelin Jun
Korea Herald
07-07-2025
- Health
- Korea Herald
S. Korea develops world's 1st recombinant anthrax vaccine
South Korea has developed the world's first recombinant protein-based anthrax vaccine, a major step toward self-sufficiency that could also open export markets for the new vaccine with fewer side effects, the government said. The Korea Disease Control and Prevention Agency partnered with private firm GC Biopharma Corp. to develop the vaccine that, unlike conventional versions, eliminates the risk of exposure to toxins produced by Bacillus anthracis, a high-risk pathogen considered a potential bioterrorism agent. The new vaccine, Barythrax inj., received regulatory approval from the Ministry of Food and Drug Safety in April. The approval allows South Korea to produce its own supply for the first time, ending its reliance on imports, the KDCA said at a press conference held last week. "As demonstrated during the COVID-19 pandemic, infectious diseases can spread rapidly and cause massive damage in a short period of time. This underscores the importance of securing proactive response capabilities at the national level," said Kim Gab-jung, director general of the KDCA's department of disease diagnosis and analysis. Kim said the achievement would help reduce vaccine import costs and enable faster, more stable responses in the event of national emergencies such as bioterrorism. "Beyond infectious disease preparedness, the vaccine's development represents a major contribution to strengthening the country's overall public health security," the official said. When asked whether tensions with North Korea factored into the vaccine's development, she said it was not specifically aimed at a potential attack from the North, but rather designed for national public health crisis preparedness. "But one thing is clear: more thorough preparedness is required, as South Korea faces a different geopolitical situation compared to many other countries," she said. Until now, South Korea had relied on imports of Biothrax, the US-made anthrax vaccine produced by Emergent BioSolutions Inc. Regarding future stockpiles, the official said, "All newly secured doses will come from domestic vaccines, although specific plans cannot be disclosed at this stage." On top of domestic stockpiling, the KDCA and GC Biopharma expect some overseas demand for Barythrax from countries without the capability to produce their own anthrax vaccines. Demand is expected to rise globally, as anthrax remains a public health concern -- particularly in regions experiencing recent outbreaks. In 2023, Zambia reported more than 600 cases, while Uganda confirmed 251 in 2024. Laos, Thailand and the Democratic Republic of the Congo have also reported fatalities in recent years. "To replace existing anthrax vaccine products on the market, we will focus on further improving product competitiveness and strengthening marketing activities to export Barythrax," said Lee Jae-woo, chief development officer at GC Biopharma's Development Division. He added that the anthrax vaccine is part of GC Biopharma's social contribution efforts, noting that the company has earned significant profits from its varicella and influenza vaccines, its major revenue drivers. The KDCA began basic research on anthrax vaccines in 1997, and GC Biopharma, formerly Green Cross, joined the development effort in 2002. Together, they invested a combined 30 billion won ($22 million) in the project. Unlike traditional anthrax vaccines, Barythrax uses a non-toxin-producing strain of Bacillus brevis to produce only the protective antigen, the key to immunity. This method significantly reduces exposure to toxins and side effects, making the vaccine safer and more cost-effective than existing options. No anthrax cases have been reported in South Korea since it was designated a notifiable disease in 2000. GC Biopharma primarily exports varicella and influenza vaccines, as well as specialty drugs, such as Aliglo for treating immunodeficiency and Hunterase for treating hemophilia. The company's sales rose 3.3 percent on-year to 1.68 trillion won last year, with exports accounting for 380 billion won, or 23 percent of the annual revenue. (Yonhap)
Korea Herald
31-05-2025
- Health
- Korea Herald
GC Biopharma's Phase 3 Clinical Trial Results for Hunterase Published in SCIE-Indexed Journal
YONGIN, South Korea, May 30, 2025 /PRNewswire/ -- GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase (idursulfase beta), its investigational drug for Hunter Syndrome (MPS II), have been published in Genetics in Medicine, an SCIE-indexed journal. Conducted at Samsung Medical Center, the Phase 3 clinical trial enrolled 24 newly diagnosed Hunter Syndrome patients with no prior treatment. It evaluated the efficacy and safety of Hunterase over a one-year treatment period. Hunter Syndrome is a rare genetic disorder caused by a deficiency of iduronate-2-sulfatase (IDS), an enzyme critical for glycosaminoglycan (GAG) catabolism. This deficiency leads to the progressive accumulation of GAGs in various organs and tissues, resulting in multisystemic dysfunction, including joint stiffness and hepatosplenomegaly. The clinical trial results demonstrated that Hunterase significantly enhanced functional mobility, reduced urinary GAG concentrations, and markedly alleviated hepatosplenomegaly. In the 6-Minute Walk Test (6-MWT), the primary endpoint of the study, patients treated with Hunterase walked an average of 62.2 meters more after treatment. This improvement was more than eight times greater compared to the placebo group, which saw an average increase of just 7.3 meters. The 6-MWT measures the distance a patient can walk on a flat surface within 6 minutes. It is a widely used clinical measure for evaluating functional mobility, cardiopulmonary function, muscle strength, and overall physical health. In the context of Hunter syndrome, it serves as a standardized and meaningful indicator of disease progression and quality of life. In addition to the primary endpoint, the study also achieved positive outcomes in secondary endpoints, including changes in urinary total glycosaminoglycan (GAG) levels, as well as heparan sulfate (HS) and dermatan sulfate (DS) levels. The GAG levels decreased by 71%, while HS and DS levels decreased by 89% and 88%, respectively. Moreover, liver and spleen volumes were reduced by 27% and 26%, respectively, demonstrating the drug's effectiveness in addressing organ enlargement commonly associated with the disease. Hunterase also demonstrated a favorable safety profile. Most adverse events were mild or moderate, and no patients discontinued treatment due to side effects. Notably, only 19% of the patients had neutralizing antibodies detected three or more consecutive times, which is significantly lower than the 62.5% observed with the existing treatments. This suggests that Hunterase may offer a more sustained therapeutic effect compared to other currently available therapy. "This clinical trial is especially meaningful as it represents the first Phase 3 study in Asian patients to validate the clinical efficacy of Hunterase", said Professor Young Bae Sohn of Ajou University School of Medicine and Ajou University Hospital, the journal's first author. "The results showed significant clinical improvement not only in metabolic markers but also in organ size normalization and restoration of physical mobility." "We are thrilled to publish our encouraging phase 3 clinical trial results", stated Jae Uk Jeong, Head of R&D at GC Biopharma. "Hunterase, developed in Korea using our proprietary technology, has the potential to significantly improve the lives of patients with Hunter syndrome." Hunter Syndrome is an X-linked lysosomal storage disorder, affecting approximately 1 in 100,000 male births. In severe cases, the patients experience early death before they reach adulthood, highlighting the need for early diagnosis and treatment. Currently, two treatments are widely available worldwide for Hunter Syndrome: GC Biopharma's Hunterase and Takeda's Elaprase. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo™(intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.
Malaysian Reserve
30-05-2025
- Health
- Malaysian Reserve
GC Biopharma's Phase 3 Clinical Trial Results for Hunterase Published in SCIE-Indexed Journal
YONGIN, South Korea, May 30, 2025 /PRNewswire/ — GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase (idursulfase beta), its investigational drug for Hunter Syndrome (MPS II), have been published in Genetics in Medicine, an SCIE-indexed journal. Conducted at Samsung Medical Center, the Phase 3 clinical trial enrolled 24 newly diagnosed Hunter Syndrome patients with no prior treatment. It evaluated the efficacy and safety of Hunterase over a one-year treatment period. Hunter Syndrome is a rare genetic disorder caused by a deficiency of iduronate-2-sulfatase (IDS), an enzyme critical for glycosaminoglycan (GAG) catabolism. This deficiency leads to the progressive accumulation of GAGs in various organs and tissues, resulting in multisystemic dysfunction, including joint stiffness and hepatosplenomegaly. The clinical trial results demonstrated that Hunterase significantly enhanced functional mobility, reduced urinary GAG concentrations, and markedly alleviated hepatosplenomegaly. In the 6-Minute Walk Test (6-MWT), the primary endpoint of the study, patients treated with Hunterase walked an average of 62.2 meters more after treatment. This improvement was more than eight times greater compared to the placebo group, which saw an average increase of just 7.3 meters. The 6-MWT measures the distance a patient can walk on a flat surface within 6 minutes. It is a widely used clinical measure for evaluating functional mobility, cardiopulmonary function, muscle strength, and overall physical health. In the context of Hunter syndrome, it serves as a standardized and meaningful indicator of disease progression and quality of life. In addition to the primary endpoint, the study also achieved positive outcomes in secondary endpoints, including changes in urinary total glycosaminoglycan (GAG) levels, as well as heparan sulfate (HS) and dermatan sulfate (DS) levels. The GAG levels decreased by 71%, while HS and DS levels decreased by 89% and 88%, respectively. Moreover, liver and spleen volumes were reduced by 27% and 26%, respectively, demonstrating the drug's effectiveness in addressing organ enlargement commonly associated with the disease. Hunterase also demonstrated a favorable safety profile. Most adverse events were mild or moderate, and no patients discontinued treatment due to side effects. Notably, only 19% of the patients had neutralizing antibodies detected three or more consecutive times, which is significantly lower than the 62.5% observed with the existing treatments. This suggests that Hunterase may offer a more sustained therapeutic effect compared to other currently available therapy. 'This clinical trial is especially meaningful as it represents the first Phase 3 study in Asian patients to validate the clinical efficacy of Hunterase', said Professor Young Bae Sohn of Ajou University School of Medicine and Ajou University Hospital, the journal's first author. 'The results showed significant clinical improvement not only in metabolic markers but also in organ size normalization and restoration of physical mobility.' 'We are thrilled to publish our encouraging phase 3 clinical trial results', stated Jae Uk Jeong, Head of R&D at GC Biopharma. 'Hunterase, developed in Korea using our proprietary technology, has the potential to significantly improve the lives of patients with Hunter syndrome.' Hunter Syndrome is an X-linked lysosomal storage disorder, affecting approximately 1 in 100,000 male births. In severe cases, the patients experience early death before they reach adulthood, highlighting the need for early diagnosis and treatment. Currently, two treatments are widely available worldwide for Hunter Syndrome: GC Biopharma's Hunterase and Takeda's Elaprase. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo™(intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. GC Biopharma Contacts (Media) Sohee Kimshkim20@ Yelin Junyelin@ Yoonjae Nayjy6520@
